MedPath

CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON

🇫🇷France
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.chu-dijon.fr

The Benefits of Virtual Reality in the Care of Elderly People With Psychomotor Disadaptation Syndrome

Not Applicable
Not yet recruiting
Conditions
Psychomotor Disadaptation Syndrome
First Posted Date
2025-06-18
Last Posted Date
2025-06-18
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
50
Registration Number
NCT07026890

Study of the Impact of HYPOglycaemia on Sarcopenia in CIRrhosis

Not yet recruiting
Conditions
Cirrhosis
First Posted Date
2025-04-29
Last Posted Date
2025-04-29
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
200
Registration Number
NCT06948656
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

POlycythemia, Proteins and ErYthropoiesis

Recruiting
Conditions
Erythropoiesis
Interventions
Biological: Collection of tube bottoms from blood samples taken in the clinic
First Posted Date
2025-04-01
Last Posted Date
2025-04-01
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
400
Registration Number
NCT06905106
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France

Recruiting
Conditions
Newborn Screening Programmes for Rare Diseases
First Posted Date
2025-03-13
Last Posted Date
2025-05-14
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
5000
Registration Number
NCT06875089
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

CHU Besançon, Besançon, France

🇫🇷

CHU Dijon Bourgogne, Dijon, France

and more 2 locations

PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy with Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients with Resected Ampullary Adenocarcinoma

Phase 3
Not yet recruiting
Conditions
Ampullary Adenocarcinoma
Interventions
Drug: mFOLFORINOX
Drug: Capecitabine or gemcitabine
Biological: Biological assessment
Diagnostic Test: Paraclinical examinations
First Posted Date
2025-02-07
Last Posted Date
2025-02-07
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
294
Registration Number
NCT06813976
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

A Placebo-controlled Evaluation of Low Dose Lithium Carbonate in Patients with TBR1-related Neurocognitive Disorders

Phase 1
Not yet recruiting
Conditions
Proven Pathogenic or Probably Pathogenic TBR1 Variant
Interventions
Other: Observation phase
Drug: Lithium treatment
Biological: biological monitoring
First Posted Date
2025-01-15
Last Posted Date
2025-01-15
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
12
Registration Number
NCT06776848
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Aspirin in Acute Pneumonia in the Elderly: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial.

Phase 3
Not yet recruiting
Conditions
Elderly Person
Acute Pneumonia
Interventions
Drug: Acetylsalicylic acid/Aspirin (100 mg)
Drug: Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
First Posted Date
2025-01-14
Last Posted Date
2025-01-14
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
600
Registration Number
NCT06774846

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Phase 3
Recruiting
Conditions
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
Interventions
Radiation: radiotherapy
Biological: Biological study on circulating tumor DNA (optional for the patient)
First Posted Date
2025-01-07
Last Posted Date
2025-02-18
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
68
Registration Number
NCT06762405
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Choice of Anticoagulant for Primary Hemostasis Studies with PFA200® (Platelet Function Analyser)

Recruiting
Conditions
Hemostasis
Interventions
Biological: Sampling of 3 additional BAPA tubes
First Posted Date
2024-12-31
Last Posted Date
2025-01-22
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
100
Registration Number
NCT06753838
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

Implementation of a Tumor Response Assessment Program Integrating the Shared Medical Decision Into the Organ Preservation Strategy for Rectal Cancer Patients

Not Applicable
Recruiting
Conditions
Rectal Cancer
First Posted Date
2024-12-18
Last Posted Date
2025-04-09
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Target Recruit Count
270
Registration Number
NCT06740357
Locations
🇫🇷

CHU Dijon Bourgogne, Dijon, France

© Copyright 2025. All Rights Reserved by MedPath